Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the
Novo Nordisk Ties Up With Vivtex in $2.1B Oral Obesity Drug Pact
Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesday.
Deal Structure and Strategic Rationale
Under the partnership, the privately held company will license some of its oral drug-delivery technology, while Novo Nordisk will take charge of global development and commercialization.
Licensing Technology
Deal Value and Milestones
Therapeutic Focus
Roles and Responsibilities
Partnership Terms
Here are some details:
* Novo Nordisk will make an undisclosed upfront payment toVivtex under the deal, besides milestone payments and royaltieson future product sales. * The partnership aims to make oral forms of biologic drugsthat would otherwise be given as injections by improving howthey are absorbed in the gut. * Vivtex's platform uses gut-screening tests, deliverytechnologies and AI tools to help make biologic drugs work aspills, the companies said. * Novo currently offers GLP-1 drugs for obesity and type 2diabetes, including Wegovy, Ozempic and the oral diabetes drugRybelsus. * In January, the Danish drugmaker launched Wegovy pill, theworld's first oral drug for obesity, in the U.S.Reporting and Editing Credits
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
